Company Summary - ReGen Therapeutics PLC (LSE:RGT)
5.75p
0.00p
FTSE AIM All Share Pharmaceuticals & BiotechnologyMarket cap: £868,652.50
Review a company's summary page in more detail and see the key fundamentals at a glance. Sign-up to Premium now to make your investment decisions.
Sign-up to Premium's Free 7 Day trial See an improved company summary
Summary
Drug development and ancillary services, and conducting pharmacokinetic and pharmacodynamic research
| Financials - Interim (23/9/2008) | ||
|---|---|---|
| Turnover | £m | 0.09 |
| Pre-tax Profit | £m | -1.12 |
| EPS | p | -9.75 |
| DPS | p | 0.00 |
| Director | Board Role |
|---|---|
| Percy Lomax | Chairman |
| Norman Lott | Finance Director & Company Sec |
Products Brands & Subsidiaries
Products & Brands
Colostrinin
Subsidiaries
Georgiades Biotech Ltd; The Georgiades Foundation Ltd; ReGen Biotech Ltd; Guildford Clinical Pharmacology Unit Limited...
Free Annual Reports
The PrecisionIR Group Annual Reports Service provides you with quick access to annual reports and other information on selected companies.
Broker Sentiment (0 brokers)
No current consensus recommendation available.
| Heading | Date |
|---|---|
| Results of General Meeting | 06/01/2009 |
| ReGen Therapeutics GBP2M Credi... | 05/01/2009 |
| Issue of Equity | 05/01/2009 |